Goldenwell Biotech (GWLL) Return on Sales (2020 - 2025)
Goldenwell Biotech's Return on Sales history spans 6 years, with the latest figure at 129.01% for Q3 2025.
- For Q3 2025, Return on Sales rose 18388.0% year-over-year to 129.01%; the TTM value through Sep 2025 reached 129.01%, up 18388.0%, while the annual FY2024 figure was 946.03%, 88211.0% down from the prior year.
- Return on Sales reached 129.01% in Q3 2025 per GWLL's latest filing, down from 33.56% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 2073.53% in Q1 2025 to a low of 10172.2% in Q1 2021.
- Average Return on Sales over 5 years is 522.29%, with a median of 80.0% recorded in 2023.
- Peak YoY movement for Return on Sales: surged 1008810bps in 2022, then tumbled -35016bps in 2024.
- A 5-year view of Return on Sales shows it stood at 6.02% in 2021, then tumbled by -242bps to 20.61% in 2022, then tumbled by -288bps to 80.0% in 2023, then plummeted by -438bps to 430.16% in 2024, then surged by 70bps to 129.01% in 2025.
- Per Business Quant, the three most recent readings for GWLL's Return on Sales are 129.01% (Q3 2025), 33.56% (Q2 2025), and 2073.53% (Q1 2025).